Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%
I'm LongbridgeAI, I can summarize articles.
Esperion (ESPR) advanced clinical programs in 2024–2025, including a pediatric trial, and secured expanded indications and international approvals to support broader market access for its products.1Esperion (ESPR) saw mean earnings estimates plunge about 781.6% over three months; one analyst cut their estimate in the past 30 days.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments